Q/C Technologies, Inc. (NASDAQ: QCLS)

Q/C Technologies, Inc. is engaged in the development and commercialization of therapeutic platforms based on well defined biological targets, including Isomyosamine and Supera CBD, and has recently shifted its strategic focus to energy efficient blockchain and cryptocurrency infrastructure through quantum class laser based computing.

The company intends to generate revenue from its laser based computing business through hardware sales, leasing arrangements, and service based offerings, including access to LPU based computing capacity via subscription or usage based models, while its legacy pharmaceutical business may produce revenue from licensing, partnerships, or potential divestiture of its therapeutic candidates such as Isomyosamine and Supera CBD.

The company operates through the following segments: Laser Based Computing Business and Pharmaceutical Business.

• Laser Based Computing Business: This segment focuses on the development, deployment, and commercialization of laser processing units (LPUs), including the qc LPU100, which utilize photonic processing to perform complex computations for blockchain infrastructure, decentralized physical infrastructure networks (DePin Tokens), and artificial intelligence driven high performance computing applications.

• Pharmaceutical Business: This segment comprises the company's therapeutic development programs, including Isomyosamine, a clinical stage small molecule targeting immunometabolic regulation for autoimmune diseases such as age related frailty and sarcopenia, and Supera CBD, a synthetic cannabinoid analog being developed for epilepsy, pain, and anxiety or depression through CB2 receptor, opioid receptor, and monoamine oxidase type B modulation.

In the laser based computing market, Q/C Technologies competes with established semiconductor firms producing CPUs, GPUs, and specialized AI hardware, as well as emerging companies developing photonic, optical, and quantum computing technologies, and with providers of blockchain infrastructure and decentralized computing solutions; the company believes its LPU based approach offers advantages in energy efficiency, processing speed, and scalability for computationally intensive workloads. In the pharmaceutical arena, the company faces competition from biotechnology and pharmaceutical firms developing TNF alpha inhibitors and cannabinoid based therapeutics, and its competitive position relies on its intellectual property portfolio covering Isomyosamine and Supera CBD and its ability to advance these candidates through clinical development.

The laser based computing business targets customers in blockchain infrastructure, decentralized physical infrastructure networks (DePin Tokens), and artificial intelligence and high performance computing sectors, including operators of decentralized compute networks and entities seeking energy efficient solutions for complex computational tasks. The pharmaceutical business serves patients with autoimmune diseases such as age related frailty and sarcopenia, individuals suffering from epilepsy, pain, and anxiety or depression, as well as healthcare providers and research institutions involved in the development and distribution of therapeutic treatments.